Mann Brukner Aniv, Ben-Hur Tamir, Honig Asaf, Ekstein Dana, Eyal Sara
Transporter Laboratory, Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel.
Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Front Pharmacol. 2018 Sep 21;9:1054. doi: 10.3389/fphar.2018.01054. eCollection 2018.
The antiepileptic drug valproate has been shown to affect the expression of carriers for essential compounds and drugs in extracerebral tissues. The aim of the current study was to evaluate the effect of valproate treatment on the cerebral expression of carriers and selected genes of the blood-brain barrier (BBB) in the rat. Male Wistar rats were treated daily for 7 days by intraperitoneal injections of valproate (75, 150, or 300 mg/kg/day) or the vehicle. mRNA was isolated from the cerebral cortex and the hippocampus. Transcript levels of 37 genes were measured using a customized gene expression assay. Quantitative histone acetylation was evaluated by western blotting. Glucose6-phosphate (G6P) tissue levels were used as a surrogate of cerebral glucose concentrations. Valproate treatment was associated with significant reduction (up to 22%; < 0.05) in cortical and hippocampal claudin 5-normalized (Glut1) mRNA expression. G6P levels were not significantly altered, but were correlated with transcript levels ( = 0.499; < 0.02). None of the other 36 screened genes were significantly affected by valproate. Cortical histone hyperacetylation indicated cerebral activity of valproate on a major pathway regulating gene expression ( < 0.02). The effect of valproate on nutrient carriers appears to be tissue-specific and even brain area-specific. If validated in humans, the changes in Glut1 expression might have clinical implications in positron emission tomography (PET) imaging. Further studies are required for elucidating the relevance of these findings to the clinic.
抗癫痫药物丙戊酸盐已被证明会影响脑外组织中必需化合物和药物载体的表达。本研究的目的是评估丙戊酸盐治疗对大鼠血脑屏障(BBB)载体和选定基因脑内表达的影响。雄性Wistar大鼠每天腹腔注射丙戊酸盐(75、150或300mg/kg/天)或赋形剂,持续7天。从大脑皮层和海马体中分离mRNA。使用定制的基因表达检测方法测量37个基因的转录水平。通过蛋白质印迹法评估组蛋白乙酰化定量。葡萄糖6-磷酸(G6P)组织水平用作脑葡萄糖浓度的替代指标。丙戊酸盐治疗与皮层和海马体中紧密连接蛋白5标准化的(Glut1)mRNA表达显著降低(高达22%;P<0.05)相关。G6P水平没有显著改变,但与转录水平相关(r=0.499;P<0.02)。其他36个筛选基因均未受到丙戊酸盐的显著影响。皮层组蛋白高度乙酰化表明丙戊酸盐在调节基因表达的主要途径上具有脑内活性(P<0.02)。丙戊酸盐对营养载体的影响似乎具有组织特异性,甚至脑区特异性。如果在人体中得到验证,Glut1表达的变化可能在正电子发射断层扫描(PET)成像中具有临床意义。需要进一步研究以阐明这些发现与临床的相关性。